NOTTINGHAM HALL LEASE AGREEMENT BY AND BETWEEN NOTTINGHAM HALL IC, LLC AS LANDLORD AND VIAMET PHARMACEUTICALS, INC. AS TENANT May 16, 2012Lease Agreement • February 1st, 2016 • Viamet Pharmaceuticals Holdings LLC • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made and entered into as of the 16th day of May, 2012, by and between NOTTINGHAM HALL IC, LLC, a Georgia limited liability company (“Landlord”), whose address is c/o American Real Estate Partners, 4505 Emperor Boulevard, Durham, North Carolina 27703, Attention: Property Manager, Fax No. , and VIAMET PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”), whose address is 2250 Perimeter Park, Suite 320, Morrisville, NC 27650, Fax No. 919-467-8540, Attention: Mr. Neil Moore (prior to the Commencement Date) and thereafter shall be 4505 Emperor Boulevard, Suite 300, Durham, North Carolina 27703, Attention: Mr. Neil Moore (the address of the Premises within the Building). Subject to all of the terms, provisions, covenants and conditions of this Lease, and in consideration of the mutual covenants, obligations and agreements contained in this Lease, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • February 1st, 2016 • Viamet Pharmaceuticals Holdings LLC • Pharmaceutical preparations • North Carolina
disapprove the Space Plan within five (5) business days after the date Landlord receives the Space Plan. If Landlord does not approve the Space Plan, Landlord will inform Tenant’s Architect and Tenant in writing of its objections and Tenant will coordinate with Tenant’s Architect to revise the same and deliver a corrected version to Landlord for its approval within five (5) business days after the date Tenant receives Landlord’s disapproval notice. The approval and revision process for the revised Space Plan shall be the same as described in the previous two sentences.
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • February 1st, 2016 • Viamet Pharmaceuticals Holdings LLC • Pharmaceutical preparations
METALLOPHILE™ TECHNOLOGY LICENSE AGREEMENTMetallophile™ Technology License Agreement • February 1st, 2016 • Viamet Pharmaceuticals Holdings LLC • Pharmaceutical preparations • Delaware
This Metallophile™ Technology License Agreement (“Agreement”), effective as of October 13, 2014 (the “Effective Date”), is entered into by and between VPS-1, Inc., a Delaware corporation with a principal place of business at 4505 Emperor Blvd., Suite 300, Durham, North Carolina 27703 (“Primary”), and Innocrin Pharmaceuticals, Inc. (originally incorporated as Hephestics, Inc. and formerly known as Viamet Pharmaceuticals, Inc.), a Delaware corporation with a principal place of business at 4505 Emperor Blvd., Suite 300, Durham, North Carolina 27703 (“Legacy”). Primary and Legacy may collectively be referred to as the “Parties” (and each, as a “Party”).
SEPARATION AND DISTRIBUTION AGREEMENT dated as of October 13, 2014 entered into by and among VIAMET PHARMACEUTICALS HOLDINGS, LLC, INNOCRIN PHARMACEUTICALS, INC. and Innocrin Pharmaceuticals Holdings, LLCSeparation and Distribution Agreement • February 1st, 2016 • Viamet Pharmaceuticals Holdings LLC • Pharmaceutical preparations • Delaware
This SEPARATION AND DISTRIBUTION AGREEMENT, dated as of October 13, 2014 (this “Agreement”), is entered into by and among Viamet Pharmaceuticals Holdings, LLC, a Delaware limited liability company (“Viamet”), Innocrin Pharmaceuticals, Inc. (f/k/a Viamet Pharmaceuticals, Inc.), a Delaware corporation (“Innocrin”), and Innocrin Pharmaceuticals Holdings, LLC, a Delaware limited liability company (“SpinCo”). Each of Viamet, SpinCo and Innocrin are sometimes referred to herein as a “Party,” and Viamet, SpinCo and Innocrin are sometimes referred to herein collectively as the “Parties.” Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in ARTICLE 1 of this Agreement.
